Clinicopathologic features associated with human papillomavirus/pl6 in patients with metastatic squamous cell carcinoma of the anal canal

Oncologist

Volumn 20, Issue 11, 2015, Pages 1247-1252

  Morris, Van K ^a   Rashid, Asif ^a   Rodriguez Bigas, Miguel ^a   Das, Prajnan ^a   Chang, George ^a   Ohinata, Aki ^a   Rogers, Jane ^a   Crane, Christopher ^a   Wolff, Robert A ^a   Enga, Cathy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal canal; Anus neoplasms; Human papillomavirus; Immunohistochemistry; In situ hybridization; p16

Indexed keywords

PROTEIN P16;

ADULT; ANUS CANCER; ARTICLE; CANCER STAGING; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; WART VIRUS; AGED; ANAL CANAL; ANUS TUMOR; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; KAPLAN MEIER METHOD; METABOLISM; PATHOGENICITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; VIROLOGY;

AGED; ANAL CANAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS;

EID: 84946553998     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0091     Document Type: Article

References (48)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Johnson LG, Madeleine MM, Newcomer LM et al. Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973-2000. Cancer 2004;101:281-288.
3. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:20400-2049.
4. Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 1996;14: 2527-2539.
5. Schiller DE, Cummings BJ, Rai S et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007;14: 2780-2789.
6. Das P, Bhatia S, Eng C et al. Predictors and patterns of recurrence after definitive chemoradiation foranal cancer. IntJ Radiat Oncol Biol Phys2007; 68:794-800.
7. Mullen JT, Rodriguez-Bigas MA, Chang GJ et al. Results of surgical salvage after failed chemoradia-tion therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 2007;14:478-483.
8. Eng C. Anal cancer: Current and future methodology. Cancer Invest 2006;24:535-544.
9. Cummings BJ. Metastatic anal cancer: The search for cure. Onkologie 2006;29:5-6.
10. Frisch M, Glimelius B, van den Brule AJ et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350-1358.
11. DeVuyst H, Clifford GM, Nascimento MC et al. Prevalence and type distribution of human papillo-mavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. IntJ Cancer 2009;124:1626-1636.
12. Hoots BE, Palefsky JM, Pimenta JM et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375-2383.
13. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012;61:258-261.
14. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteinswith p53. Science 1990;248:76-79.
15. Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded by human papilloma-virus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
16. Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996;70:4509-4516.
17. Ruiz S, Santos M, Segrelles C et al. Unique and overlappingfunctionsof pRband p107 in the control of proliferation and differentiation in epidermis. Development 2004;131:2737-2748.
18. Balsitis SJ, Sage J, Duensing S et al. Recapitulation of the effects of the human papillo-mavirustype 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol 2003;23:9094-9103.
19. Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: Where cancer meets the cell cycle. Exp Biol Med (Maywood) 2006;231: 1271-1281.
20. Ajani JA, Wang X, Izzo JG et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010;55:1098-1105.
21. Daling JR, Madeleine MM, Johnson LG et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101: 270-280.
22. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-1510.
23. Sunesen KG, Norgaard M, Thorlacius-Ussing O et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978-2005. Int J Cancer 2010; 127:675-684.
24. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342:792-800.
25. Kjaer SK, Frederiksen K, Munk C et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 2010;102:1478-1488.
26. Rodriguez AC, Schiffman M, Herrero R et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst 2010;102:315-324.
27. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
28. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
29. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110:1429-1435.
30. Daling JR, Madeleine MM, Johnson LG et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. IntJ Cancer 2005;116:606-616.
31. Sarkar FH, Miles BJ, Plieth DH et al. Detection of human papillomavirus in squamous neoplasm of the penis. J Urol 1992;147:389-392.
32. Gargano JW, Wilkinson EJ, Unger ER et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 2012;16: 471-479.
33. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269.
34. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28: 4142-4148.
35. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapyand survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-1998.
36. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Reviewand meta-analysis. IntJ Cancer 2007;121:1813-1820.
37. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oro-pharyngeal cancer. N Engl J Med 2010;363:24-35.
38. Serup-Hansen E, Linnemann D, Skovrider-Ruminski Wetal. Human papillomavirusgenotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014;32:1812-1817.
39. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
40. Yhim HY, Lee NR, Song EKetal.The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 2011;129:1752-1760.
41. Tseng HF, Morgenstern H, Mack TM et al. Risk factors for anal cancer: Results of a population-based case-control study. Cancer Causes Control 2003;14:837-846.
42. Barnholtz-Sloan J, Patel N, Rollison D et al. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129-1138.
43. Ghebeh H, Mohammed S, Al-Omair A et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-198.
44. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005;104:2084-2091.
45. Cho YA, Yoon HJ, Lee JI et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011;47:1148-1153.
46. Lyford-Pike S, Peng S, Young GD et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733-1741.
47. Elam-Evans LD, Yankey D, Jeyarajah J et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2013. MMWR Morb Mortal Wkly Rep 2014;63:625-633.
48. Joura EA, Giuliano AR, Iversen OE et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-723.